Weekly Analysts’ Ratings Updates for Rhythm Pharmaceuticals (RYTM)

Rhythm Pharmaceuticals (NASDAQ: RYTM) has recently received a number of price target changes and ratings updates:

• 11/6/2026 – Rhythm Pharmaceuticals had its price target lowered by JPMorgan Chase & Co. from $145.00 to $142.00. They now have an “overweight” rating on the stock.
• 11/5/2026 – Rhythm Pharmaceuticals had its price target raised by Guggenheim from $143.00 to $147.00. They now have a “buy” rating on the stock.
• 11/4/2026 – Rhythm Pharmaceuticals had its “market perform” rating reaffirmed by Oppenheimer.
• 11/4/2026 – Rhythm Pharmaceuticals had its “outperform” rating reaffirmed by Royal Bank Of Canada.
• 11/4/2026 – Rhythm Pharmaceuticals had its price target raised by Citizens Jmp from $160.00 to $166.00. They now have a “market outperform” rating on the stock.
• 11/3/2026 – Rhythm Pharmaceuticals had its price target lowered by Needham & Company LLC from $130.00 to $114.00. They now have a “buy” rating on the stock.
• 10/16/2026 – Rhythm Pharmaceuticals is now covered by William Blair. They set an “outperform” rating on the stock.
• 10/15/2026 – Rhythm Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/15/2026 – Rhythm Pharmaceuticals had its price target lowered by JPMorgan Chase & Co. from $146.00 to $145.00. They now have an “overweight” rating on the stock.
• 10/12/2026 – Rhythm Pharmaceuticals had its price target raised by HC Wainwright from $105.00 to $130.00. They now have a “buy” rating on the stock.
• 10/8/2026 – Rhythm Pharmaceuticals had its price target raised by Royal Bank Of Canada from $155.00 to $159.00. They now have an “outperform” rating on the stock.
• 9/17/2026 – Rhythm Pharmaceuticals is now covered by Wolfe Research. They set an “outperform” rating on the stock.
• 9/14/2026 – Rhythm Pharmaceuticals is now covered by Leerink Partners. They set an “outperform” rating and a $133.00 price target on the stock.

Rhythm Pharmaceuticals Stock Up 0.4%

Shares of Rhythm Pharmaceuticals stock traded up $0.45 on Monday, hitting $112.72. The stock had a trading volume of 403,166 shares, compared to its average volume of 848,912. The stock has a market cap of $7.82 billion, a price-to-earnings ratio of -38.87 and a beta of 2.17. Rhythm Pharmaceuticals, Inc. has a twelve month low of $74.50 and a twelve month high of $122.20. The business’s 50 day moving average is $96.15 and its two-hundred day moving average is $97.25.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.61) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.10. The firm had revenue of $92.13 million for the quarter, compared to analyst estimates of $85.56 million. Rhythm Pharmaceuticals had a negative return on equity of 171.16% and a negative net margin of 69.03%. The company’s revenue for the quarter was up 79.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.82) EPS. As a group, equities analysts predict that Rhythm Pharmaceuticals, Inc. will post -4.24 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Jennifer Lee sold 75,834 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $117.38, for a total value of $8,901,394.92. Following the transaction, the executive vice president directly owned 54,233 shares in the company, valued at approximately $6,365,869.54. This represents a 58.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO David Meeker sold 50,000 shares of the firm’s stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $102.67, for a total transaction of $5,133,500.00. Following the transaction, the chief executive officer directly owned 239,258 shares in the company, valued at approximately $24,564,618.86. This represents a 17.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 258,450 shares of company stock valued at $28,796,497 in the last 90 days. 5.90% of the stock is currently owned by corporate insiders.

Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts, and its work centers on the melanocortin-4 receptor pathway, which helps regulate hunger and energy balance.

Its commercial product, IMCIVREE (setmelanotide), is approved in the United States and Europe for certain forms of genetically defined obesity, including obesity associated with Bardet-Biedl syndrome and specific gene deficiencies.